| Followers | 843 |
| Posts | 123010 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Tuesday, January 11, 2022 1:45:08 PM
VIR slide set from JPM:
https://investors.vir.bio/static-files/7ecf45fb-6918-4cf8-9a02-b8c12183ca4f
https://investors.vir.bio/static-files/7ecf45fb-6918-4cf8-9a02-b8c12183ca4f
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent VIR News
- Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 • Business Wire • 05/18/2026 08:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/16/2026 01:00:01 AM
- "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies • GlobeNewswire Inc. • 05/14/2026 02:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:11:32 PM
- Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results • Business Wire • 05/06/2026 08:05:00 PM
- Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference • Business Wire • 05/05/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/30/2026 09:43:20 PM
- Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results • Business Wire • 04/23/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/16/2026 12:49:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/16/2026 12:46:30 PM
- Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer • Business Wire • 04/16/2026 12:05:00 PM
- Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer • Business Wire • 04/13/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/10/2026 08:01:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 08:50:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 07:23:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 08:35:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 07:49:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/23/2026 01:42:56 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 09:01:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 02:01:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 10:20:20 PM
